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During the 20th century a number of medical discoveries have been 
made that have a tremendous effect of the everyday life of the average 
people (in addition to their scientific merits). These include the 
development of assisted reproduction therapies that provide a hope for 
infertile couples.  
During the past two decades the age when women give birth to their 
first child increased significantly due to a number of socio-economic 
factors. One of the major drawbacks of this tendency is that the fertility of 
an older woman is impaired. In addition, older women’s often have an 
older partner whose fertility may be also frequently impaired. 
Consequently, the number of pairs requiring assisted reproduction therapies 
is dramatically increasing. 
According to an old ‘bon mot’ a woman is able to doalmost 
everything for two things: to have a child and to not have a child. As an 
expert of assisted reproduction therapies I can fully reinforce this 
experience. 
When at 1st March, 1999 I first entered to the Outpatient Clinic of 
Fertility at Szent Janos Hospital, my first observation was the crowded 
room full with heterogeneous pairs; some of them just learned the success 
of the intervention, while others faced with the fail of the therapy. This 
scene is still present for me as it clearly indicates how close are the success 
and fails, happiness and sadness in this field of medicine.  
My task is to increase the rate of successful interventions of assisted 
reproduction therapies. During my professional career I should regularly 
up-date my knowledge with latest advances in the field and to transfer them 
to the practice as soon as possible. During my Theses I summarize my 
experience related with this work. 
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AIMS 
 
ART including IVF is a dynamically developing scienc . Therefore 
when I first participated in the therapy of infertile women in 1st March, 
1999, the therapeutic and diagnostic arsenal available t that time differed 
significantly from those available nowadays. In addition, the safety and 
efficacy of some of the regimes used nowadays routinely were also not 
assessed that time.  
The aim of my PhD work was to clarify some practical questions 
affecting the technique and success of IVF in the following areas. 
 
A. Are the results in term of pregnancy rates obtained with 
GnRH antagonist protocol comparable to those with GnRH 
agonist long protocol during IVF? 
B. Is the pregnancy rate with IVF treatment altered if 
recombinant hCG is given instead of urinary hCG? 
C. Which protocol for the pretreatment of endometry before the 
implantation of frozen-thawed embryo is the most effective 
approach in term of pregnancy rate? 
D. Does β-hCG values measured on day 14 after fertilization of 
oocyte have any predictive value during IVF therapy? 
E. What are the limitations of ultrasound when ectopic IVF-ET 
pregnancies are assessed? 
F. Is the risk of adnex torsion increased after an IVF-ET? 
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A Are the results in term of pregnancy rates obtained with 
GnRH antagonist protocol comparable to those with GnRH 
agonist long protocol during IVF? 
 
GnRH antagonist protocols have several advantages ov r the GnRH 
agonist long protocols. The administration of GnRH antagonists is 
substantially shorter and simpler, less gonadotropin is required to reach 
controlled hyperstimulation of the ovaries (COH) and the risk of OHSS is 
also low. Further advantage is the maintained endogen us LH levels that 
allow to perform the stimulation with recFSH alone. In our Centre we are 
applying GnRH antagonist protocols for IVF since May, 2000. Analyzing 
the clinical data of patients treated in our Centre we analyzed whether the 
efficacy of GnRH antagonist protocols corresponds to that published by 
other institutes. 
 
Patients and methods* 
We retrospectively analyzed the data of IVF cycles performed 
between 1st July, 2004 and 28th, February, 2005 with the aim to compare 
the outcomes after IVF long protocols and the recently introduced 
antagonist protocols.  
In case of IVF long protocols we started the s.c. administration of 
triptoreline, a GnRH analogue agonist (0.1 mg/day) in the midluteal phase, 
up to the required downregulation of hypophyseal receptor, then until the 
day of oocyte retrieval.  
In case of antagonist protocols we started the s.c. administration of 
ganirelix, a GnRH antagonist on Day 5 of the cycle (0.25 mg/day) until the 
day of oocyte retrieval. COH was performed by the administration of 
recFSH and hMG in a ratio of 3:1. The dose of recFSH was based on 
patients’ age, body mass index, basal FSH levels and ultrasound (US) 
findings of the ovaries. Oocyte retrievals were performed 35 hours later. 
Oocytes were fertilized with IVF techniques or, in case of specific sperm 
characteristics, with ICSI techniques. Luteal phase was supported with 
intravaginally administered micronized progesterone (P).  
                                                
* All studies performed within the frame of my PhD work were approved by the 
competent Institutional Ethical Committee. 
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Results 
The results are summarized in Table 1.  
 Antagonist protocol 
Long 
protocol 
Level of 
signi- 
ficance 
Number of treated patients 136 314  
Age (year) 32.6 ± 4.2 31.4 ± 4.0 p<0.05 
BMI (kg/m²)  22.4 ± 3.1 22.8 ± 3.4 ns 
Basal FSH (IU/L) 6.7 ± 1.8 6.4 ± 1.6 ns 
Serum E2 level on day of 
hCG administration (pg/ml) 
2232 ± 926 2757 ± 816 p<0.001 
Endometrium thickness on 
the day of hCG 
administration (mm) 
11.3 ± 1.6 12 ± 2 p<0.001 
Amount of FSH-HMG used 
(NE) 
1851 ± 917 
2411 ± 
1065 
p<0.001 
Number of metaphase II 
oocytes 
6.5 ± 3.4 8 ± 3.0 p<0.001 
Number of zygotes 5.1 ± 3.0 5.9 ± 2.7 p<0.01 
Number of transferred 
embryos  
2.45 ± 1.0 2.75 ± 0.8 p<0.01 
Rate of ongoing 
pregnancies 
29.8% (n = 
37) 
30.8% (n = 
92) 
ns  
 
Rate of pathological 
pregnancies 
16.9% (n = 
23) 
13.0% (n = 
41) 
ns 
Rate of cancelled cycles 
8.8% (n = 
12) 
4.8% (n = 
15) 
ns 
Rate of severe OHSS  0.8% (n = 1) 
1.6% (n = 
5) 
Ns 
 
Table 1. Outcomes in patients treated with antagonist or long protocol (mean ± SD) 
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Discussion 
 
Our retrospective analysis demonstrated that during cycles of 
patients subjected to antagonist protocols the serum estradiol (E2) levels 
are significantly lower, and the number of mature follicles, MII oocytes and 
embryos available for embryo transfer (ET) are also lower compared to 
those subjected to agonist protocols. An explanatio for the difference may 
be that the antagonist therapy is initiated on Day 2-3 of menstrual cycle, in 
that phase when the spontaneous follicular recruitmen  occurs in the 
presence of intact endogenous LH secretion. In spite of the differences 
observed in hormone levels our analysis indicates that he pregnancy 
outcomes after IVF with antagonist protocols are comparable to those after 
the ’gold standard’ long protocols. 
The benefits of GnRH antagonist protocols over GnRH agonist 
protocols include patients’ better compliance to GnRH antagonists; the 
shorter duration of therapy; the lower prevalence of OHSS. In addition, 
lower gonadotropin doses are required. Based on comparable pregnancy 
results we concluded that GnRH antagonist protocols an be safely and 
effectively used for COH.  
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B. IS THE PREGNANCY RATE WITH IVF TREATMENT 
ALTERED IF RECOMBINANT HCG IS GIVEN INSTEAD OF 
URINARY HCG? 
A number of well designed randomized clinical studies (RCT) 
demonstrated the bioequivalence of urinary and recombinant hCG products 
(uhCG and rhCG, respectively). RCTs compare different treatment 
protocols under well controlled conditions in a highly selected patient 
population, therefore, the results obtained do not reflect necessarily the real 
life conditions (i.e. they are observer in a more heterogeneous population, 
without the absolute availability of monitoring tools, otherwise required for 
an RCT). Therefore, in addition to RCTs, further non-interventional 
(observational) studies are also needed to reinforce the comparable efficacy 
of rhCG and uhCG products.  
 
Patients and methods* 
In our center colleagues performing IVF can freely decide whether 
they use rhCG or uhCG in a well defined patient population. We evaluated 
the outcomes of IVF therapies done with rhCG or uhCG products between 
February, 2008 and January, 2009. 
 
Results 
In the evaluated period 803 IVF interventions were performed in our 
Centre. We excluded unresponsive or obese patients; tho e above 40 years 
of age; and those with an FSH level >12 NE/ml (n = 296), as our 
Institutional Guidelines recommends the preferential use of rhCG in this 
population. Clinical signs and symptoms suggesting OHSS occurred in 15 
and 3 of rhCG and uhCG treated patients, respectively. The implantation 
should have been cancelled due to concomitant disease in two patients. 
Finally, the pregnancy outcomes were compared in 391 and 96 patients 
treated with rhCG and uhCG, respectively (see Table 2). 
 
Discussion 
The results of our observational study indicate that the rate of 
pregnancies verified by laboratory tests increases by about 13% when 
rhCG products are used. In addition, we also detectd an about 7% (not 
significant) increase in pregnancies entering the 24th week of gestation.   
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803 women subjected to 
IVF between  
02/2008 and 01/2009 
  
 
 excluded from the analysis: N =  
  Poor responder 98 
  obese (BMI ≥30 kg/m2) 80 
  At least 40 years of age 95 
  FSH ≥12 IU/ml 23 
  OHSS risk 18 
  intercurrent disease 2 
 
  316 
 
487 women in the analysis   
Clinical characteristics   
 rhCG uhCG  
n = 391 96  
Age (years) 32.5 ±3.5 33.3 ±3.7  
BMI (kg/m2) 21.9 ±2.6 22.5 ±2.6  
No. of previous 
attempts 1±1 0.5 ±1  
Endometrium 
thickness (mm) 12 ±2 11.5 ±2  
Therapeutic characteristics   
GnRH agonists 159 46  
GnRH antagonists 232 50  
6500 IU dose 100 -  
9750 IU dose 253 -  
13000 IU dose 38 -  
Pregnancy outcomes Total: 
Laboratory verified 
pregnancy (n =) 169 29* 198 
Pregnancy over 
24th g.w (n =) 110 20 130 
Laboratory verified 
pregnancy (%) 43% 30% 40.6% 
Pregnancy over 
24th g.w (%) 28% 21% 26.7% 
p = 0.021, Chi-square-test 
 
Table 2. Patient enrolment, clinical characteristics and outc mes. Abbreviations: rhCG: 
recombinant human chorionic gonadotropin; uHCG: urinary human chorionic gonadotropin; 
BMI: body mass index; GnRH: gonadotrop-releasing hormone; IU: international unit; g.w: 
gestational week 
 
As these patients were highly heterogeneous, these ob rvations were 
adjusted for patients’ clinical characteristics. The associations remained 
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significant and the beneficial impact of rhCG on ong i g became almost 
significant as well. Although our retrospective analysis does not allow the 
exact determination of underlying cause, it is reason ble to postulate that 
one factor responsible for increased success rate my be the possibility of 
individualized therapy with rhCG products, as rhCG products are available 
in different dosing formulations. In addition, the batch variability of rhCG 
products is negligible (in contrast with uhCG products). 
 
C. WHICH PROTOCOL FOR THE PRETREATMENT OF 
ENDOMETRY BEFORE THE IMPLANTATION OF FROZEN-
THAWED EMBRYO IS THE MOST EFFECTIVE APPROACH IN 
TERM OF PREGNANCY RATE? 
 
Different IVF centres apply different approaches and protocols for 
the pre-treatment of endometry with gonadotropins / GnRH agonists before 
the implantation of frozen-thawed embryo (FET). The aim of our 
retrospective data analysis was to elucidate whether success rates after FET 
based on natural, programmed or stimulated cycles differ. 
 
Methods* 
 
FET was applied in women with natural cycles (ovulating women), 
or after pre-treatment with E2 and P or after a hMG/rFSH stimulated cycle. 
If the size of oocyte was larger than 20-24 mm and e ometrial thickness 
was higher than 10 mm, 10,000 IU rhCG or hCG was administered.  
FET was performed on Day 17 – 20 of the cycle. At this ime point P 
was given to support luteal phase. In women with hormonally manipulated 
cycles down-regulation was performed during the mid-luteal phase of 
preceding cycle. Then the development of endometry was supported with 
the administration of 17 β E2 in increasing doses until the thickness of 
endometry reached 8 mm. At this time P was administered to support the 
luteal phase; FET was performed on Day 17 – 20. In women treated with 
hMG or rFSH the hormonal therapy was performed with low doses (75 and 
50 IU/day, respectively). The dose of gonadotrop hormone was gradually 
increased until the developing oocyte’s diameter and E2 levels were 
sufficiently large (i.e. 17 – 18 mm and >300–350 pg/ml, respectively). 
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Ovulation was induced by the administration of 5,000 - 10,000 IU rhCG or 
uhCG and 3 days later FET was performed. Luteal phase was supported by 
P in this protocol. 
 
Results 
Between 2002 and 2007 we applied 2207 FET cycles. In average, a 
30% pregnancy rate was detected (668 pregnancies from 2207 FET) (Table 
3). The type of protocol used for pre-treatment of endometry had no 
significant effect on pregnancy rate; however, thisrate was tended to be the 
highest with natural cycle. 
 
 Cycle No. Successful 
pregnancy 
Pregnancy 
rate 
Protocol applied 
Natural cycle 1068 374 35% 
Programmed 
cycle 
558 156 28% 
Stimulated cycle 581 138 24%. 
Implanted embryo 
D3 embryos 1953 572 29% 
D5 embryos 254 96 38% 
 
Table 3. Pregnancy rates with FET cycles 
 
The highest pregnancy rate of 38% was reached with the implantation of 
D5 embryos; the pregnancy rate with D3 embryos was nominally lower 
(29%). 
Comparing the different protocols used for pre-treatment of endometry no 
difference in result was detected; however, nominally the highest 
pregnancy rate occurred with spontaneous cycles without administration of 
any drug. 
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Discussion 
 
A number of factors have an impact on success rate after FET cycles. 
One of the still unclarified issues is whether exogenous administration of 
E2 may improve results obtained with natural cycles. The results of our 
analysis reinforce our earlier observations done in our Institute and in other 
centres: the success rates are comparable after natural-cycle based, 
programmed or stimulated protocols. This suggests that hormonal support 
does not increase the rate of pregnancies. Instead, he success rate was 
nominally higher by about 9% after natural cycles.  
Protocols used for pre-treatment of endometry during FET should be 
decided always after careful consideration of the patient’s individual needs. 
In case of a sequentially designed FET the first step is always the approach 
based on spontaneous natural cycles; if this is unsuccessful, the next steps 
are the programmed and stimulated cycles. 
 
 
D. DOES BETA HCG VALUES MEASURED ON DAY 14 AFTER 
FERTILIZATION OF OOCYTE HAVE ANY PREDICTIVE VALUE 
DURING IVF THERAPY? 
 
The several attempts with ART and IVF may present an almost 
intolerable strain for the infertile couple, therefore it is a must to have a 
definitive and early data about the success of therapy. The measurement of 
β-hCG levels is a possible candidate. However, literary data and current 
practice in Hungary are not unequivocal regarding the timing of β-hCG 
measurements after a blastocyst culture. β-hCG levels in the same 
embryonal age are lower following blastocyst transfer than those measured 
after ’traditional’ transfers performed on Day 2-3 after oocyte retrieval or 
in spontaneous pregnancies. The explanation of this p enomenon is the 
lower cell volume after blastocyst culturing compared to ’traditional’ 
transfers or spontaneous pregnancies.  
The blastocyst cultures were introduced in our Centre at the 
beginning of 1999. We performed an analysis in 2002 in order to elucidate 
the predictive value of β-hCG levels on Day 14 after oocyte retrieval. 
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Patients and methods* 
 
Between 2nd January, 2001 and 31st December, 2002 we measured 
increased β-hCG levels on Day 14 after oocyte retrieval in 520 patients 
after IVF-ET treatment. ET was performed on Day 2, 3 or 5 after 
fertilization. β-hCG levels were measured on Day 14 after oocyte retrieval. 
The level of detection was 2 IU/L. Pregnancies were biochemical, if the 
only sign was an increased hCG level without further clinical signs and 
symptoms or characteristic US signs. Clinical pregnancy was defined as the 
presence of US signs of in utero embryo, its heart functions or extrauterine 
pregnancy. 
 
Results 
Out of the 520 cases, the number of clinical and biochemical pregnancies 
was 382 (73.5%) and 138 (26.5%), respectively. 
 
β-hCG levels measured on Day 14 after oocyte retrieval indicate that 
if 45 IU/L is used as cut-off value, the sensitivity and specificity of β-hCG 
levels for the discrimination between clinical and biochemical pregnancies 
are 91.1% and 89.9%, respectively. 
 
Discussion 
 
The single measurement of β-hCG levels on Day 14 after oocyte 
retrieval is suitable exclusively for the prediction f clinical pregnancies 
and early pregnancy loss in singular pregnancies (Figure 1). In multiple 
pregnancies, however, this parameter does not help to assess the risk of 
gemini reduction and/or early pregnancy loss. 
In the analyzed period the rate of extrauterine pregnancies after IVF-
ET was 2,6% (that is lower than the internationally reported 4-5% rate). Of 
note, in 8 of 10 extrauterine pregnancies the β-hCG levels were below 
45 NE/L (median value of β-hCG was 32.4 NE/l). In monitoring and 
follow-up of these cases the value of a single determination of β-hCG on 
Day 14 after oocyte retrieval may be limited, as the early recognition of 
extrauterine pregnancies is in fact based on serial β-hCG measurements 
and, above 1025 IU/L β-hCG levels, on highly sensitive US techniques. 
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Figure 1. β-hCG levels according to induced pregnancies. TRIG = trigemini, 
AB = abortus, TRIG – GEM = trigemini – gemini reduction, EXTRAUT = 
extrauterine, SINGLE = singular pregnancies 
 
E. WHAT ARE THE LIMITATIONS OF ULTRASOUND WHEN 
ECTOPIC IVF-ET PREGNANCIES ARE ASSESSED? 
 
The recent spread of highly sensitive US instruments and transvaginal 
transducers improved our capability to early recognitio  of extrauterine 
pregnancies. As a result, the role of previously used tandard classical 
methods such as abrasion or puncture of Douglas cavity in the detection of 
extrauterine pregnancies decreased. However, we should be aware of the 
limitations of US technique and the diagnostic value of the serially 
determined β-hCG levels. 
 
Methods* 
 
In general, the first US test is performed on the 5th week of gestation. 
The rationale behind this practice is to recognize th  early extrauterine 
pregnancies after IVF-ET; it is well known, that this complication is more 
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frequent in ART compared to spontaneous pregnancies (2-11% IVF-ET 
versus 0,6-0,8%). If US suggests no in utero pregnancy, β-hCG levels are 
measured immediately. Based on β-hCG levels we make any of the 
following decisions:  
1. Watchful waiting with serial measurement of β-hCG levels on every 
second day. 
2. MTX treatment under strict monitoring of β-hCG levels and US control. 
3. Hospitalization and, in case of necessity, immediat  laparoscopy 
(laparotomy). If salpingectomy is not performed, further β-hCG 
measurements are done to establish the efficacy of intervention. 
Of course, Decision 1 or 2 is made when an intact egg sac is detected in 
any tube, or, in its absence, there is no echo suggestin  bleeding in the 
Douglas cavity.  
 
Results 
 
Between 2nd January, 2001 and 30th April, 2008 we performed 6647 
IVF-ETs. Extrauterine pregnancy was detected in 45 cases (representing 
2.06% of all the 2189 clinical pregnancies). 
The geometric mean of β-hCG measured on Day 14 of pregnancy 
was 36.3 IU/L in these 45 extrauterine gravities. (In our previous analysis, 
45 IU/L was that cut-off value that had 91.1% sensitivity and 89.9% 
specificity for the discrimination between biochemical and ongoing 
pregnancies). In 42 patients we were able to monitor β-hCG levels. The 
normal doubling time of 1.4 – 2.1 days was measured just in 8 subjects. 
 
Discussion 
 
Transvaginal US technique provides an opportunity to visualize in 
utero or, sometimes, the extrauterine sac, provided that β-hCG levels are 
above 1025 IU/L. However, even colour coded Doppler technique is not 
appropriate for the identification of pregnancies when β-hCG levels are 
<800-1000 IU/L. A warning sign of extrauterine pregnancies is when the 
first β-hCG level is low, does not correlate with gestational age or when the 
doubling time of serial β-hCG levels is delayed (i.e. consecutive β-hCG 
levels do not increase exponentially). 
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Serial measurement of β-hCG levels as a complementary technique 
to vaginal US provides an opportunity to recognize and monitor 
extrauterine pregnancy and, also, helps to assess the efficacy of 
methotrexate therapy. Our data indicate that just one third of all 
extrauterine pregnancies could be diagnosed by US in early phase and two-
thirds of them β-hCG measurements are required to diagnose this 
complication. Therefore, irrespectively of the use of highly sensitive US 
techniques one should also measure repeatedly β-hCG levels to diagnose 
and monitor IVF-ET ectopic pregnancies. One cannot overemphasize how 
important is to establish this diagnosis in the possibly earliest phase in an 
era of laparoscopic surgical interventions. 
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F. IS THE RISK OF ANNEX TORSION INCREASED AFTER AN 
IVF-ET? 
 
Our efforts during IVF treatment cycles aim to obtain multiple 
mature oocytes. As a result of COH the volume and mass of ovaries are 
dramatically increased and several fold higher than t t of the normal. The 
large ovaries resembling to Ementhaler cheese are filled with lutein cysts. 
In case of pregnancy (that is characterized by susceptibility for systemic 
oedema and looser connective tissues) the large ovaries increase the risk of 
annex torsion. However, this complication is quite rare; in another 
Hungarian IVF centre one case was reported after 5132 IVF-ET treatments. 
In our centre, 3 cases with annex torsion occurred f om 2926 IVF-ET 
therapy. 
 
These cases required dramatically different interventional approach 
because of different anatomical situation and different gynaecological 
expertise. Laparoscopy was performed in 2 of the 3 cases (of those, 1 was 
terminated by laparotomy). However, the interventions were successful and 
allowed the development of healthy pregnancies. (Each of this pregnancies, 
however, also supported by P up to 12th week of gestation; then the 
luteoplacentar shift successfully occurred.) 
These cases indicate that in pregnancies after ART the risk of annex 
torsion is increased. During early pregnancy after IVF-ET one should 
rather suspect annex torsion in the presence of chara teristic signs and 
symptoms of annex torsion such as lower abdominal cramps. The very 
early recognition of torsion provides an opportunity to perform an up-to-
date, laparoscopic and organ-sparing intervention fr detorquation. If 
conservative approach is decided, in addition to the decrease of the size of 
the ovary one should perform the fixation of ovaries in order to prevent any 
relapse of this condition.  
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THESES 
 
1. The successful pregnancy rates after controlled ovary 
hyperstimulation with GnRH agonist long protocol orGnRH 
antagonist protocol during IVF (ICSI)-ET are comparable. 
2. The use of recombinant hCG (rhCG) during IVF 
treatment leads to a significantly greater rate of laboratory 
verified pregnancies and a numerically greater rateof clinical 
pregnancies in comparison with the use of urinary hCG (uhCG). 
3. During frozen-thawed embryo transfers there is no 
significant difference in clinical pregnancy rates after different 
protocols used for the preparation of endometry. There is a 
tendency, however, that the highest rate of pregnancy is achieved 
with protocols based on natural cycles.  
4. On Day 14 after the oocyte retrieval the laboratory 
verified pregnancies and clinical pregnancies can be distinguished 
with a specificity and sensitivity of 89.9% and 91.1%, 
respectively, if the cut-off level of serum β-hCG is 45 IU/L. 
5. Transvaginal ultrasound is not a suitable tool t recognise 
exactly the presence of ectopy pregnancy early; however, serial β-
hCG measurements provide an opportunity to diagnose 
extrauterine gravidity that, hence, can be operated in intact state. 
In addition to patient’s monitoring with serial β-hCG and 
ultrasound the wait-and-see approach and medical therapy 
(including methotrexate) are also justified and canbe used safely. 
6. During the early phase of pregnancies initiated with 
artificial reproduction therapies the annexes should be assessed 
with extra caution with transvaginal ultrasound in order to early 
recognize the warning signs of annex torsion as the incidence of 
this complication is higher than the average after controlled ovary 
hyperstimulation as it is also suggested by our cases. 
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